Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Cancer J. 2022 May-Jun;28(3):208–223. doi: 10.1097/PPO.0000000000000591

Figure 14.

Figure 14

Meta-analysis of randomized controlled trials of lipid-lowering therapy in which secondary (8 trials of 8,272 women) and primary (6 trials of 11,435 women) cardiovascular disease prevention trials were analyzed separately in women (33). Although lipid-lowering therapy statistically significantly reduces cardiovascular events in secondary prevention in women, lipid-lowering does not statistically significantly reduce such events in primary cardiovascular disease prevention. All-cause mortality is unaffected by lipid-lowering therapy in women in secondary and primary cardiovascular disease prevention. CHD = coronary heart disease; MI = myocardial infarction; CI = confidence interval